Epithalon Dosage Guide

Epithalon (Ala-Glu-Asp-Gly) is a synthetic version of epithalamin, a peptide naturally produced by the pineal gland. Research by Professor Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology has demonstrated that epithalon activates telomerase — the enzyme that elongates telomeres, the protective caps at the ends of chromosomes that shorten with each cell division.

In multiple studies, epithalon has demonstrated the ability to increase telomere length, normalize circadian rhythms, restore melatonin production, and extend lifespan in animal models. A 15-year human study in elderly patients showed a 28% reduction in mortality in the epithalamin-treated group compared to controls.

The dosing protocol is based on Khavinson's published research:

The most commonly cited protocol is 5–10 mg daily for 10–20 consecutive days, repeated every 4–6 months. This cyclical approach mirrors the protocols used in Khavinson's clinical studies. Total per-cycle dosing ranges from 50–200 mg.

Epithalon is administered once daily, typically in the evening to align with pineal gland activity and melatonin regulation:

• Evening injection: 1–2 hours before bedtime is the most common protocol.
• Morning injection: Some protocols use morning administration, though evening is theoretically preferred.

Cycling: Epithalon is always used in short, defined cycles: 10–20 days of daily injection, then off for 4–6 months before repeating. This mimics the cyclical protocols used in published research. Most researchers perform 2–3 cycles per year.

• Step 1: Swab vial stoppers with alcohol.
• Step 2: For a 50 mg vial, add 2 mL BAC water to yield 25 mg/mL (5 mg per 0.2 mL).
• Step 3: Direct the stream along the glass wall.
• Step 4: Gently swirl until dissolved. Solution should be clear.
• Step 5: Store at 2–8°C. Use within 14–21 days.

Administer via subcutaneous or intramuscular injection. Subcutaneous injection into the abdominal fat pad is standard. Some protocols use intranasal administration, though bioavailability data for this route is limited.

• 5 mg/day: Extremely well-tolerated. Minimal reported side effects in published studies. Improved sleep quality commonly reported.
• 10 mg/day: Occasional injection site irritation. Some researchers report transient drowsiness or vivid dreams. No significant adverse events documented in clinical literature.

Khavinson's 15-year study and other long-term research have not identified any significant safety concerns with the standard cyclical dosing protocol. Epithalon has one of the cleanest safety profiles among research peptides.

Epithalon is for research purposes only and has not received FDA approval.

While the safety profile appears favorable based on available research, long-term human safety data from large-scale controlled trials is lacking. The telomerase-activating mechanism warrants caution in subjects with active malignancies, as cancer cells frequently upregulate telomerase. Consult a healthcare provider before initiating any protocol.